Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma

NCT00089115 is registered in ClinicalTrials.gov with Favrille as lead sponsor.

NCT NCT00089115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00089115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma
Lead sponsor
Favrille
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2004
Completion date
Not reported
Enrollment
Not reported
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma